Cerdwen Ventures · Life Sciences Evaluator
"The public should always be wondering how it is possible for a company to give so much for the price it charges." — Henry Ford
Internal VC Tool
Connecting...
Company Profile
Pipeline status:
Screening
Diligence
IC Review
Invested
Passed

Market Intelligence

Powers TAM calculation and Investment Memo. Enter what you know — fields are optional.

HighEV Value Dimensions

Score each dimension relative to the incumbent. 5 = massive improvement, 3 = moderate, 1 = minimal or parity.

$
Financial Value
Cost to payer, system, and patient vs. incumbent
—
▼
Cost to payer / patient
How much cheaper vs. current standard? Equal cost for better outcome counts.
3
Same cost or more10× cheaper
Healthcare system savings
Reduces downstream costs — hospitalizations, readmissions, long-term care?
3
No changeMassive downstream savings
Reimbursement / pricing power
Likelihood of payer coverage; ability to command premium vs. generics.
3
Poor coverage likelyHighly reimbursable
⚙
Effort Value
Burden on physician, patient, and care team
—
▼
Physician workflow friction
Special training, new equipment, prior authorization vs. current practice?
3
Major disruptionSeamless adoption
Patient compliance burden
How easy is it for patients to use/adhere vs. incumbent?
3
Much harderMuch easier
Diagnostic / testing requirements
Requires companion diagnostics or complex biomarker testing?
3
Complex Dx neededNo extra testing
⏱
Time Value
Speed-to-benefit, treatment duration, time-to-market
—
▼
Speed-to-benefit for patient
How quickly does the patient see improvement vs. current standard?
3
SlowerDramatically faster
Duration of therapy
One-time cure vs. chronic treatment. Curative scores higher.
3
Chronic, indefiniteOne-time / curative
Regulatory approval timeline
BTD, Orphan, RMAT pathways score higher.
3
10+ yrs standard pathAccelerated pathway
⚠
Risk Value
Clinical, safety, execution and adoption uncertainty
—
▼
Safety profile vs. incumbent
Novel mechanism + small safety DB = physician hesitation 2–5 yrs post-approval.
3
Worse / unknownClearly safer
Clinical evidence strength
Head-to-head P3 RCT data scores highest. Hypothesis only scores lowest.
3
Hypothesis onlyHead-to-head P3 RCT
IP / moat defensibility
Patents, trade secrets, regulatory exclusivity vs. generic / me-too risk.
3
Easily replicatedStrong multi-layer moat
Manufacturing / scalability risk
Complex biologics, cell therapies score harder.
3
Highly complexProven, scalable
✓
Functional Value
Objective clinical outcomes vs. standard of care
—
▼
Absolute clinical benefit magnitude
OS, PFS, HbA1c, pain scores. Relative improvements only count if absolute is meaningful.
3
Marginal / surrogateOrder-of-magnitude better
Unmet need severity
Last-line therapy for fatal disease vs. incremental in well-treated condition?
3
Well-treated conditionNo current options
Addressable patient population
Breadth of patients who qualify. TAM proxy.
3
Ultra-rare (<1K)100M+ globally
◎
Psychological Value
KOL enthusiasm, patient demand, brand, social signaling
—
▼
Physician / KOL enthusiasm
"I need this" vs "interesting" — the most reliable early commercial signal.
3
"Interesting" — indifferent"I need this" — strong pull
Patient demand / advocacy
Will patients seek this out? Patient advocacy tailwinds?
3
Passive marketHigh patient pull
Brand / narrative strength
Being "best practice" is a moat in medicine.
3
Generic / commodityCategory-defining

FDA Approval vs. Adoption Risk Modifier

~20–40% of approved drugs see limited uptake. Approval risk ends at the FDA; market risk starts there.

Adoption Probability Scorecard

The 5 independent adoption filters. Failure in any one can stall uptake regardless of FDA approval.
Estimated adoption probability vs. full potential
—
HighEV Score
—
/ 100
Score your startup
Adjust sliders to calculate
0Cerdwen threshold ▶100

Projected Adoption Trajectory

🏛
Innovators
Academic centers
→
👨‍⚕️
Early Adopters
KOL specialists
→
🏥
Community
Specialty practice
→
🌍
Primary Care
Mass market scale

Market Opportunity

⚠ Investor Red Flags Detected

Investment signal analysis

Partner Notes (saved to shared database)

Save evaluation first to add notes.
Deal Pipeline
Loading pipeline...
All Evaluations
Loading evaluations...
Investment Memo
No evaluation loaded
Complete an evaluation, then click Generate Memo.
"The only repeatable method for building successful companies is delivering massive net value add to customers relative to their current way of solving the same problem." — Kevin Brophy, Cerdwen Ventures
Framework Overview

HighEV Core Principle

We analyzed five centuries of startup success and failure. Companies that win — outside of anomalous speculations — are the ones that massively outperform peers in net value add to customers relative to the current way of solving the same problem.

FDA Approval ≠ Adoption

~20–40% of FDA-approved drugs see limited real-world uptake. The FDA measures adequacy; clinical adoption requires superiority or clear differentiation. Approval risk ends at the FDA; market risk starts there.

Value Is Relative, Not Absolute

Value is relative to a decision comparing alternative means. Large changes are transformative; small changes drive marginal behavior. Our model mutes small changes and magnifies large ones — calibrated to human decision-making thresholds.

Investing Is Science

Every investment opportunity is a hypothesis. Every investment is an experiment testing, refining, and validating that hypothesis. Every trial and outcome creates knowledge leveraged forward. We put scientific principles first.

Scoring Formula
HighEV Raw = Σ(dimension_score × weight) Dimension weights: Functional Value 23% ← outcomes are king Risk Value 20% ← largest variance driver Financial Value 15% Effort Value 15% Psychological Value 15% Time Value 12% FDA Adoption Modifier = trial_design × endpoint × guideline × payer_access (range ~0.42× to 1.27×) Final HighEV Score = (Raw / 5) × 100 × FDA Modifier
Verdict Thresholds

Below 40 — Pass

Insufficient NVA. Consider fundamental redesign of value proposition.

40–59 — Monitor

Moderate value creation. Niche indications possible. Adoption probability uncertain.

60–74 — Qualified

Exceeds Cerdwen threshold. Eligible for deeper diligence and potential investment.

75+ — High Conviction

Massively outperforms incumbent. Matches Henry Ford's standard — customers wonder how the company can offer so much.

Platform Customization

Current Dimension Weights

The exact multipliers (summing to 100%) used for the Core HighEV raw score generation. Modifying these securely currently requires backend redeployment.